Therapeutic | Clazakizumab |
Target | IL6 |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS |
Light Chain | AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Phase-III |
Estimated Status (August '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Alder Biopharmaceuticals%3BCedars-Sinai Medical Center%3BMedical University of Vienna%3BVitaeris |
Conditions Approved | na |
Conditions Active | Inflammation%3BPsoriatic arthritis%3BRenal transplant rejection%3BRheumatoid arthritis |
Conditions Discontinued | Anaemia%3BCachexia%3BFatigue%3BStomatitis%3BCrohn%27s disease%3BGraft-versus-host disease |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]